Equity Research · Current Holding
UnitedHealth Group
UNH · NYSE · Managed Care · Health Services
A serial compounder handed to me at a distressed multiple because four bad headlines arrived in the same quarter.
Quan Pham · M’Squared Capital Research · August 2026
What the market is missing
The market has confused a sentiment washout with a broken franchise. A medical-loss-ratio spike, a DOJ headline cycle, a CEO transition and withdrawn guidance all hit at once, and the stock repriced from premium to distressed. What did not change is the earnings power of Optum sitting inside the largest managed-care business in the country.
Why I own it
I bought UnitedHealth because the vertical integration — insurance fused with pharmacy, care delivery and health services — is the widest moat in the sector, and I rarely get to buy it near a trough multiple on trough earnings. Elevated utilization is cyclical; pricing catches up on the January renewal cycle. Roughly 13 times normalized earnings for a mid-teens grower with more than 90% recurring revenue is a price this name almost never wears.
What has to happen
The medical-loss ratio has to stabilize in the quarterly prints, and the 2026 rate and benefit-design repricing has to restore the underwriting margin. The DOJ and regulatory overhang needs to resolve into something bounded. A new-CEO reset that reinstates guidance would do most of the work of re-rating the multiple.
What would prove me wrong
The thing I am watching is whether the cost trend is cyclical or structural. If utilization stays elevated after the repricing cycle has had time to work, then this is not a timing dislocation — it is a margin reset, and my entry multiple was on earnings that no longer exist. Further DOJ escalation or a hostile Medicare Advantage rate path would compound that.
Valuation & exit
My $500 objective is about 18× normalized 2027 earnings — still below this company's own history, on numbers I regard as depressed. The asymmetry is the whole trade: I am buying quality while the multiple, not the franchise, is broken. If the cost trend proves structural, I am wrong and I exit; if it normalizes, the re-rating and the compounding both accrue.
Position
Core Long
Price objective
$500
Sector
Managed Care
Status
Current holding
Last updated
August 2026
This note is the opinion of M’Squared Capital and is provided for informational purposes only. It is not investment advice, nor an offer or solicitation to buy or sell any security. Price targets and entry and exit levels reflect the firm’s proprietary views and realized transactions; they are not forecasts of future results. The firm may hold, add to, reduce, or close any position at any time without notice. Past performance is not indicative of future results.